Effect of pre stimulation to magnetic stimulation in treatment of old age depression and associated brain wave changes

Not Applicable

• Conditions: Health Condition 1: F332- Major depressive disorder, recurrent severe without psychotic featuresHealth Condition 2: F331- Major depressive disorder, recurrent, moderateHealth Condition 3: F321- Major depressive disorder, singleepisode, moderateHealth Condition 4: F322- Major depressive disorder, singleepisode, severe without psychotic features

• Registration Number: CTRI/2020/08/027230
• Lead Sponsor: King Georges Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Right handed persons

Willing to give written informed consent

Fulfilling the diagnoses as mentioned according to ICD 10 (F32.1/33.1 and F32.2/F33.2)

Exclusion Criteria

Any co morbid alcohol or other substance dependence except for caffeine and nicotine

Presence of psychosis

History of epilepsy/seizure

Comorbidity of severe surgical or medical illnesses not letting the patient cooperate for rTMS

Patients with cardiac pacemaker or other metal parts in body

Patients who have received ECT in the past 6 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary objective is to compare the effect of theta priming vis a vis a vis no priming on adjunctive 1 Hz rTMS over right DLPFC in treatment of late life depression. <br/ ><br>Assessments using HAM D, HAM A, GDS, Somatic symptoms scale 8, HMSE and CGI-I <br/ ><br>Timepoint: From baseline to end of week 1, 2 and 4 after initiation of intervention <br/ ><br>

Secondary Outcome Measures

Name	Time	Method
Secondary objective is to study the associated quantitative EEG changes in frontal beta and theta waves in the two groupsTimepoint: Before, at baseline and after treatment, at the end of 2 weeks